Transitional Cell Carcinoma Clinical Trial
Official title:
Detecting Transitional Cell Carcinoma From Haematuria: A Study of Urinary Tissue Factor
To validate ELISAs for the detection of urinary tissue factor (TF) in patients suspected of having bladder cancer.
The effective diagnosis of transitional cell carcinoma (TCC), the most common form of bladder
cancer, is often quite challenging, due to a lack of disease-specific symptoms. Detecting TCC
early is crucial to increase the chances of a cure. Cystoscopy, which is currently the
standard test used for urothelial cancer diagnosis, is an invasive and relatively expensive
procedure but, while several potential markers in urine have been studied with the goal of
replacing cystoscopy, no urinary marker alone or in combination with others has shown
sufficient accuracy.
In this study, levels of tissue factor (TF) isoforms will be measured by ELISA in urine
samples collected from patients referred to the haematuria clinic with visible or microscopic
haematuria. These values will be linked to the subsequent diagnosis of each patient, and used
to assess the accuracy of the ELISAs in detecting TCC when compared to standard cystoscopy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03296306 -
Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma
|
Phase 3 | |
| Completed |
NCT00880334 -
Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC
|
Phase 2 | |
| Completed |
NCT00216801 -
Relationship of Ochratoxin A to Upper Urologic Cancers
|
N/A | |
| Withdrawn |
NCT04179110 -
Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
|
Phase 2 | |
| Completed |
NCT00070070 -
Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
|
Phase 1 | |
| Completed |
NCT00154687 -
Weekly TP-HDFL in the Treatment of Advanced TCC
|
Phase 2 | |
| Withdrawn |
NCT04006691 -
Efficacy and Safety of UGN-101 in Recurrent Patients
|
Phase 3 | |
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Completed |
NCT00714025 -
A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy
|
Phase 2 | |
| Terminated |
NCT01310803 -
Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder
|
Phase 3 | |
| Completed |
NCT00623831 -
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
|
Phase 1 | |
| Completed |
NCT00173862 -
Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC
|
Phase 2 | |
| Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
| Terminated |
NCT01438112 -
Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer
|
Phase 2/Phase 3 | |
| Completed |
NCT00683059 -
Single Agent Abraxane as Second Line Therapy in Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT04811846 -
CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood
|
N/A | |
| Not yet recruiting |
NCT04878250 -
Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the Bladder
|
Phase 2 | |
| Completed |
NCT00633789 -
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
|
Phase 2 | |
| Completed |
NCT00612326 -
Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging
|
N/A | |
| Active, not recruiting |
NCT03219775 -
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma
|
Phase 2 |